Drugs / GFH312
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05991362 | Nov 2022 → Feb 2023 | — | Zhejiang Genfleet Therapeutics Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04676711 | Apr 2021 → May 2022 | poisoning | GenFleet Therapeutics (Australia) Pty Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05618691 | Dec 2022 → Dec 2023 | intermittent vascular claudication, peripheral arterial disease | Zhejiang Genfleet Therapeutics Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-09 | Genfleet Therapeutics (Shanghai) Inc. | Results 2023 ASCPT | 劲方医药将公布GFH312 单药I期临床研究数据 genfleet.com ↗
数据显示，GFH312在单一剂量和多剂量爬坡试验中安全性/耐受性良好，药代动力学/药效学特性支持后续临床开发。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-09 | Genfleet Therapeutics (Shanghai) Inc. | 2023 ASCPT | 劲方医药将公布GFH312 单药I期临床研究数据 genfleet.com ↗ |
| 2022-08-18 | Genfleet Therapeutics (Shanghai) Inc. | 劲方医药在美国启动RIPK1抑制剂（GFH312）II期临床研究 genfleet.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05618691 ↗ |
| Action | Inhibit | “GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-α downstream.” NCT04676711 ↗ |
| Modality | Small molecule | “GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-α downstream.” NCT04676711 ↗ |
| Route | Oral | “Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses” NCT04676711 ↗ |
| Target | RIPK1 | “GFH312 is a small molecule inhibitor of receptor-interacting serine/threonine protein-1(RIP1) kinase, a key regulator of the TNF-α downstream. RIPK1 can regulate the NF- κB...” NCT04676711 ↗ |